When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Optic neuritis

Последний просмотренный: 18 Feb 2026
Last updated: 06 Jun 2024

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • periorbital/retro-ocular pain
  • loss of visual acuity with scotoma
  • color desaturation/loss of color vision
  • relative afferent papillary defect (RAPD)
Полная информация

Другие диагностические факторы

  • optic disk swelling
  • neurologic abnormalities of multiple sclerosis
  • Uhthoff phenomenon
  • phosphenes
  • Pulfrich phenomenon
  • perivenous sheathing
Полная информация

Факторы риска

  • age 30 to 50 years
  • female sex
  • white ethnicity
  • HLA-DRB1*1501 genotype
  • risk factors for multiple sclerosis (MS; Epstein-Barr virus [EBV] infection, vitamin D deficiency, and smoking)
  • childhood in higher latitudes
  • presence of autoimmune disease
  • exposure to infectious diseases, such as Lyme disease and syphilis
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • MRI - brain
  • CBC
  • ESR
  • C-reactive protein
  • venereal disease research laboratory (VDRL)
  • aquaporin-4 (AQP4) antibody, myelin oligodendrocyte glycoprotein (MOG) antibody, and collapsin response mediator protein 5 (CRMP5) antibody
  • uric acid
  • serum ACE
  • ANA
  • B12 and folate
Полная информация

Исследования, проведение которых нужно рассмотреть

  • Lyme titer
  • cerebrospinal fluid analysis
Полная информация

Алгоритм лечения

Острый

acute episode

ПРОДОЛЖЕНИЕ

coexisting inflammatory diseases (e.g., NMOSD, MOGAD, SLE or sarcoidosis)

Составители

Авторы

Cris S. Constantinescu, MD, PhD

Chair of Neurology Emeritus

Academic Unit of Mental Health and Clinical Neuroscience

University of Nottingham

Nottingham

UK

Attending Neurologist

Professor of Neurology

Cooper Neuroscience Institute

Camden

New Jersey

Раскрытие информации

CSC has received research support or consultancy fees from Biogen, GW, Merck, Morphosys, Novartis, Roche, Sanofi-Pasteur, MSD, and Teva. CSC is an author of a number of references cited in this topic.

Thomas M. Bosley, MD
Thomas M. Bosley

Knights Templar Eye Foundation Professor of Ophthalmology

Wilmer Eye Institute

Johns Hopkins University

Baltimore

MD

Раскрытие информации

TMB declares that he has no competing interests.

Рецензенты

Gus Gazzard, MA, MBBChir, MD, FRCOphth

Consultant Ophthalmic Surgeon

King's College Hospital

Honorary Research Fellow

Institute of Ophthalmology

London

UK

Раскрытие информации

GG declares that he has no competing interests.

John Selhorst, MD

Professor

Department of Neurology and Psychiatry

Saint Louis University

St. Louis

MO

Раскрытие информации

JS declares that he has no competing interests.

Efstratios Mendrinos, MD

Department of Ophthalmology

Geneva University Hospitals

Geneva

Switzerland

Раскрытие информации

EM declares that he has no competing interests.

Jonathan Smith, MD

Specialist Registrar in Ophthalmology

Royal Victoria Infirmary

Newcastle

UK

Раскрытие информации

JS declares that he has no competing interests.

Peter Sguigna, MD

Assistant Professor

Department of Neurology

The University of Texas

Southwestern Medical Center

Dallas

TX

Раскрытие информации

PS has received grant support from National Multiple Sclerosis Society, International Progressive Multiple Sclerosis Alliance, National Institute of Health (NIH), Center for Translational Medicine, Physician Scientist Training Program, and Department of Defense (DOD). He has received research support from Genentech, Clene Nanomedicine, and Patient Centered Outcomes Research Institute. He has received consulting fees from Medical Logix LLC, Genentech, EMD Serono, Horizon Therapeutics, and Bristol Myers Squibb. He is the inventor on a patent for OCT technology that is held by UT Southwestern Medical Center.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Petzold A, Fraser CL, Abegg M, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022 Dec;21(12):1120-34. Аннотация

American Academy of Ophthalmology. Optic neuritis - 2012. Jul 2012 [internet publication].Полный текст

Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581-8. Аннотация

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73.Полный текст  Аннотация

Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 Aug;17(8):1019-32.Полный текст  Аннотация

Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015 Aug 14;(8):CD001430.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

内容使用需遵循免责声明